

2019  
**JMMC**  
Prague

JOINT MEETING ON MEDICINAL CHEMISTRY  
Prague, June 27–30, 2019



# FINAL PROGRAMME



**EFMC**  
European Federation  
for Medicinal Chemistry



**FACULTY OF PHARMACY  
IN HRADEC KRÁLOVÉ**  
Charles University



## puriFlash® Generation 5

**Ultra Performance Flash Purification**  
**or How to do high throughput purification?**



These Best-In-Class instruments are fully designed to make your purification Easier, Intuitive & Productive.

### Compact & Technological =>

The "Reduced Sphere of Use" improves ergonomics of the workstation. The global productivity of the working space is drastically amplified by having a lot of Integrated technologies (DEDL, UV, leak detector, ...) in such a small box.

On top of that, you can decide for a Bench-top installation of the instrument, the "Fume Encloser" feature safely optimizes the management of your workspace leaving your fume-hood free for chemistry

Versatile in terms of applications, the fine-tuning of the detection technologies employed guarantees maximum purification yield without loss of product.

### Reliable & Safe =>

Run 24/7 with Confidence for a minimum of after Sales Service required. Bad surprises or hidden costs aren't to be feared after the purchase. The cost of use is perfectly mastered.

You can stay focused on your job with the necessary peace of mind having the certainty to get the best purification as possible. There is no risk of product loss thanks to the complete monitoring of the system through sensors, the management of overpressure and pauses.

The devices will be available full time and for long term for purification.

### InterSoft® X =>

Keeps Intelligence Simple & Smart. Its Best-In-Class design makes the Chemist's life easier.

It is easily accessible to multi-profile users with a minimum of training. Intuitive, this Gen5 "Push the boundaries" with the innovative Flash & Go, Load & Go and Boost & Go technologies. To develop a method, challenge Genius or, do it by yourself.


### Genius™ =>

Your personal Artificial Intelligence, embedded in InterSoft® X generates the best eco-(logical)-purification in the current knowledge.

Run safely the method & Get your Products Pure!

### A Unique feature, the Solvent Heater technology to control & regulate temperature =>

You become confident in the reproducibility of purification methods in a given environment and their site-to-site transfer. You have access to impossible purifications at room temperature, you improve and you have a better control of the solvent mixture (thermal exo/endo mix). This feature also annihilates environmental variations and enhances efficiency, detection limit, purity, charge and the fractions collection.



Flash&Go:



Load&Go:



Boost&Go:





# CONTENT

<b>Welcome Message</b>	<b>4</b>
<b>Congress Committee</b>	<b>5</b>
<b>Congress Secretariat</b>	<b>5</b>
<b>Congress Organizers</b>	<b>6</b>
<b>Programme</b>	
<b>Thursday, June 27, 2019</b>	<b>7</b>
<b>Friday, June 28, 2019</b>	<b>8</b>
<b>Saturday, June 29, 2019</b>	<b>10</b>
<b>Sunday, June 30, 2019</b>	<b>11</b>
<b>Speakers</b>	<b>12</b>
<b>Keynote Speakers</b>	<b>15</b>
<b>Instructions for Speakers</b>	<b>18</b>
<b>Abstract Book</b>	<b>18</b>
<b>List of Posters</b>	<b>19</b>
<b>Social Events</b>	<b>28</b>
<b>Tours</b>	<b>29</b>
<b>Partners</b>	<b>30</b>
<b>Floor Plan</b>	<b>31</b>
<b>General Information</b>	<b>32</b>
<b>Good to Know</b>	<b>34</b>



## WELCOME MESSAGE

Dear colleagues, JMMC-2019 participants,

Welcome to the 11<sup>th</sup> **Joint Meeting on Medicinal Chemistry 2019** organized by the Faculty of Pharmacy, Charles University on occasion of its 50<sup>th</sup> anniversary, under the auspices of the European Federation for Medicinal Chemistry in **June 27–30, 2019 in Prague**, the heart of Europe and the capital of the Czech Republic.

In 2019, it will be 20 years of history of this traditional Joint Meetings, founded in 1999 by Prof. G. Ronsivalle (Italy) together with Prof. A. Lipkowski (Poland) and Prof. G. Toth (Hungary). On behalf of National Chemical Societies of Italy, Poland and Hungary, Prof G. Ronsivalle together with Prof. Z. Chilmonczyk (Poland) and Prof. P. Matyus (Hungary) organized the first meeting in Taormina in 1999, particularly to promote Medicinal Chemistry, attract young scientists and foster relationships between medicinal chemists of the participating countries. After Taormina, JMMC was held in Budapest 2001, Krakow 2003, Vienna 2005, Portorož 2007, Budapest 2009, Catania 2011, Lublin 2013, Athens 2015 and Dubrovnik 2017. Since the first meeting, number of participating countries has increased to nine – Austria, Croatia, Czech Republic, Greece, Hungary, Italy, Poland, Slovakia and Slovenia. The success of the last 10<sup>th</sup> JMMC 2017 (249 participants from 28 countries) illustrates an interest in this kind of meetings. We are pleased to invite medicinal chemists from all over the world, not only the participating countries, to come, stimulate discussion in drug discovery and development and to promote collaboration between medicinal chemistry scientists, both young and experienced.

The Organizing Committee wishes you a memorable stay in Prague, filled with new experience and fruitful personal contacts. Enjoy the 11<sup>th</sup> JMMC.

**Prof. RNDr. Jarmila Vinšová, Ph.D.**  
*Congress President*

**Prof. PharmDr. Martin Doležal, Ph.D.**  
*President of the Czech Pharmaceutical Society*



# CONGRESS COMMITTEE

## National Organizing Committee

Jarmila Vinšová

Martin Doležal

Radim Nencka

Martin Krátký

Jan Zitko

Marta Kučerová-Chlupáčová

## International Scientific Committee

**Marko Mihovilovic** (Vienna University of Technology, Vienna, Austria)

**Péter Mátyus** (Semmelweis University, Budapest, Hungary)

**Gabriele Costantino** (University of Parma, Parma, Italy)

**Dariusz Matosiuk** (Medical University of Lublin, Lublin, Poland)

**Danijel Kikelj** (University of Ljubljana, Ljubljana, Slovenia)

**Emmanuel Mikros** (National and Kapodistrian University of Athens, Athens, Greece)

**Andrej Boháč** (Comenius University in Bratislava, Bratislava, Slovakia)

## International Organizing Committee

**Michael Schnürch** (Vienna University of Technology, Vienna, Austria)

**Višnja Štepanić** (Ruđer Bošković Institute, Zagreb, Croatia)

**János Wölfling** (University of Szeged, Szeged, Hungary)

**Girolamo Cirrincione** (University of Palermo, Palermo, Italy)

**Katarzyna Kieć-Kononowicz** (Jagiellonian University Medical College, Kraków, Poland)

**Marko Anderluh** (University of Ljubljana, Ljubljana, Slovenia)

**Magdaléna Májeková** (Comenius University in Bratislava, Bratislava, Slovakia)

# CONGRESS SECRETARIAT

## GUARANT International spol. s r.o.

Na Pankráci 17, 140 00 Prague 4, Czech Republic

**Phone:** +420 284 001 444

**Website:** [www.guarant.com](http://www.guarant.com)



# CONGRESS ORGANIZERS

## Czech Pharmaceutical Society



## European Federation for Medicinal Chemistry



**EFMC**  
European Federation  
for Medicinal Chemistry

## Faculty of Pharmacy in Hradec Kralove



**FACULTY OF PHARMACY  
IN HRADEC KRÁLOVÉ**  
Charles University

## Charles University





# PROGRAMME

## THURSDAY, JUNE 27, 2019

**13:00–19:00**      **Registration**

**15:00–15:30**      **Opening of the Meeting**

**Moderator:** Dr. Radim Nencka


**15:30–16:15** PL-1 Prof. **Michal Hocek**: Substituted or hetero-fused 7-deazapurine nucleoside cytostatics with complex mechanism of action

**16:15–16:45** KL-1 Assoc. Prof. **Izidor Sosič**: Development of non-peptidic and subunit-selective inhibitors of immunoproteasome

**16:45–17:30** PL-2 Prof. **Jakub Fichna**: Challenges in design of novel treatment options in inflammatory bowel diseases employing gold and silver

**17:30–18:00** KL-2 Dr. **Zlatko Janeba**: Development of polysubstituted pyrimidines as potent inhibitors of prostaglandin E<sub>2</sub> production

**18:00–19:30**      **Welcome Cocktail**



## FRIDAY, JUNE 28, 2019

### **Moderator: Prof. Sanja Tomić**

**09:00–09:45** PL-3 Prof. **Szilvia Bősze**: Cargo-dependent mode of drug uptake with improved efficacy and bioavailability: the design and evaluation of target cell selective transporters and drug-conjugates

**09:45–10:15** KL-3 Dr. **Theodora Calogeropoulou**: Constrained miltefosine derivatives. The journey towards NMT-A2, a new drug lead for visceral leishmaniasis

**10:15–10:45** **Coffee break**

### **Moderator: Prof. Szilvia Bősze**

**10:45–11:30** PL-4 Assoc. Prof. **Janez Ilaš**: Inhibitors of topoisomerases: from antibacterial to anticancer agents

**11:30–12:00** KL-4 Dr. **Zsuzsa Baranyai**: Synthesis and *in vitro* biological evaluation of drug-peptide conjugates against glioblastoma

**12:00–12:30** KL-5 Assoc. Prof. **Angeliki Kourounakis**: Morpholine: A privileged scaffold for the development of multi-target bioactive molecules

**12:30–13:45** **Lunch**

**13:45–15:00** **Poster Session I (odd numbers)**

### **Moderator: Prof. Gabriele Costantino**

**15:00–15:45** PL-5 Prof. **Sanja Tomić**: The Role(s) of Dipeptidyl Peptidase III in Humans

**15:45–16:15** KL-6 Prof. **Michael Schnürch**: Leoligin-inspired Synthetic Lignans with Selectivity for Cell-type and Bioactivity, Relevant for Cardiovascular Disease

**16:15–16:45** **Coffee break**





**Moderator: Assoc. Prof. Janez Ilaš**

- 16:45–17:30** PL-6 Prof. **Gabriele Costantino**: Chasing target essentiality in the search for new antibacterials
- 17:30–18:00** KL-7 Assoc. Prof. **Martina Hrast**: Covalent warheads as new MurA inhibitors
- 18:00–18:20** L-1 **Miriam Girardini**: Characterizing a new series of efflux-pumps inhibitors as potential anti-tubercular adjuvants
- 18:20–18:40** L-2 Prof. **Barbara Nawrot**: Nanostructured conjugates of DNA oligonucleotides and boron clusters as potential dual-action anti-EGFR therapeutic nucleic acids
- 19:30–22:30** **Congress dinner**



## SATURDAY, JUNE 29, 2019

- 08:30–09:30** **Moderator: Prof. Michal Hocek**  
Invited lecture  
Dr. **Tomas Cihlar**: Discovery and Development of Antiviral Therapeutics for Emerging and Neglected Viral Infections
- 09:30–10:00** KL-8 Dr. **Jose Miguel Ferreira de Oliveira**: Regulation of cyclin and cyclin-dependent kinase expression by 3',4'-dihydroxyflavonol in human *in vitro* models
- 10:00–10:30** **Coffee break**
- 10:30–11:15** PL-7 **Moderator: Prof. Danijel Kikelj**  
Assoc. Prof. **Manolis Fouteris**: New artemisinin hybrid molecules with antileukemic and antimalarial activities
- 11:15–11:45** KL-9 Assoc. Prof. **Zrinka Rajić**: Harmicines as novel antiplasmodial leads
- 11:45–12:15** KL-10 Prof. **Tibor Kurtan**: Bioactive benzene-condensed heterocycles
- 12:15–13:15** **Lunch**
- 13:15–14:30** **Poster session II (even numbers)**
- 14:30–15:15** PL-8 **Moderator: Assoc. Prof. Vittorio Pace**  
Prof. **Yoel Rodríguez**: *In silico* Design of Chemical Modulators for Chromatin Biology
- 15:15–15:45** KL-11 Dr. **Lars Richter**: Time is running – Large scale matched molecular pair analysis to domesticate binding kinetics
- 15:45–16:15** L-3 Dr. **David Peralta**: Why Was My Paper Rejected? Tips from an Editor on How to Get Published
- 16:15–16:35** **Coffee break**
- 16:35–17:20** PL-9 **Moderator: Prof. Yoel Rodríguez**  
Assoc. Prof. **Vittorio Pace**: Building-up molecular complexity with carbenoids: New vistas in homologation chemistry
- 17:20–17:50** KL-12 Dr. **Magdaléna Májeková**: Targeting SERCA through drug design
- 17:50–18:10** L-4 Assoc. Prof. **Diego Muñoz-Torrero**: A novel class of chroman-based multitarget anti-Alzheimer hybrids: design, synthesis, *in vitro* profiling and *in vivo* proof-of-concept



## SUNDAY, JUNE 30, 2019

### Moderator: Prof. Martin Doležal

- 09:00–09:30 KL-13 Dr. **Ana Amić**: Anthraquinones as potential free radical scavengers and P-glycoprotein inhibitors
- 09:30–10:00 KL-14 Dr. **Lucia Kováčiková**: Isosteric replacement brought markedly improved selectivity of aldose reductase inhibitors
- 10:00–10:30 KL-15 Dr. **Jan Zitko**: Structural modifications of pyrazinamide – rational design towards new potential anti-microbial compounds
- 10:30–10:50 L-5 Dr. **Muhammed İhsan Han**: Design, synthesis and biological activity evaluation of aryl-sulfonylthiosemicarbazides as antiproliferative agents and COX-2 inhibitors

### 10:50–11:20 Coffee break

### Moderator: Dr. Jan Zitko

- 11:20–11:50 KL-16 Prof. **Agostino Marrazzo**: From haloperidol to new selective sigma receptor ligands
- 11:50–12:20 KL-17 Dr. **Anna Wieckowska**: Serotonin 5HT-6 receptor antagonists and cholinesterase inhibitors with A $\beta$  antiaggregation properties in the development of multifunctional ligands against Alzheimer's disease
- 12:20–12:40 L-6 **Belgin Sever**: New pyrazoline derivatives clubbed with thiazole scaffold as anticancer agents targeting EGFR
- 12:40–13:00 L-7 Dr. **Constantin Tanase**: New carbocyclic nucleoside analogues with an optically active substituted bicyclo[2.2.1]heptane fragment as a glycoside moiety linked to the base by a methylene group

### 13:00–13:30 Winning Posters Flash presentations

### 13:30–14:00 Closing

# SPEAKERS

## Invited Lecture

### Discovery and Development of Antiviral Therapeutics for Emerging and Neglected Viral Infections



**Dr. Tomas Cihlar**

*Vice President of Virology at Gilead Sciences, San Francisco Bay Area, USA*

## Plenary Lecture

### Cargo-dependent mode of drug uptake with improved efficacy and bioavailability: the design and evaluation of target cell selective transporters and drug-conjugates



**Prof. Szilvia Bősze**

*MTA-ELTE Research Group of Peptide Chemistry, Eötvös Loránd University, Budapest, Hungary*

## Plenary Lecture

### Chasing target essentiality in the search for new antibacterials



**Prof. Gabriele Costantino**

*Professor of Medicinal Chemistry and Director of Department of Food and Drugs, University of Parma, Parma, Italy*

**Plenary Lecture**

**Challenges in design of novel treatment options in inflammatory bowel diseases employing gold and silver**



**Prof. Jakub Fichna**

*Medical University Lodz, Lodz, Poland*

**Plenary Lecture**

**New artemisinin hybrid molecules with antileukemic and antimalarial activities**



**Assoc. Prof. Manolis Fousteris**

*Assistant Professor in Medicinal Chemistry, Department of Pharmacy, University of Patras, Patras, Greece*

**Plenary Lecture**

**Substituted or hetero-fused 7-deazapurine nucleoside cytostatics with complex mechanism of action**



**Prof. Michal Hocek**

*Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic*

**Plenary Lecture**

**Inhibitors of topoisomerases: from antibacterial to anticancer agents**



**Assoc. Prof. Janez Ilaš**

*Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia*

**Plenary Lecture**

**Building-up molecular complexity with carbenoids: new vistas in homology chemistry**



**Assoc. Prof. Vittorio Pace**

*Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria*

**Plenary Lecture**

**In silico Design of Chemical Modulators for Chromatin Biology**



**Prof. Yoel Rodríguez**

*Department of Natural Sciences, Hostos Community College of CUNY, New York, USA*

**Plenary Lecture**

**The Role(s) of Dipeptidyl Peptidase III in Humans**



**Prof. Sanja Tomić**

*Head of Laboratory for Protein Biochemistry and Molecular Modelling, Ruđer Bošković Institute, Zagreb, Croatia*



## KEYNOTE SPEAKERS

### Austria

Dr. Lars Richter

*University of Vienna*

**TIME IS RUNNING – LARGE SCALE MATCHED MOLECULAR PAIR ANALYSIS TO DOMESTICATE BINDING KINETICS**

Prof. Michael Schnürch

*Institute of Applied Synthetic Chemistry, Vienna University of Technology*

**LEOLIGIN-INSPIRED SYNTHETIC LIGNANS WITH SELECTIVITY FOR CELL-TYPE AND BIOACTIVITY, RELEVANT FOR CARDIOVASCULAR DISEASE**

### Croatia

Dr. Ana Amić

*Josip Juraj Strossmayer University of Osijek*

**ANTHRAQUINONES AS POTENTIAL FREE RADICAL SCAVENGERS AND P-GLYCOPROTEIN INHIBITORS**

Assoc. Prof. Zrinka Rajić

*Faculty of Pharmacy and Biochemistry, University of Zagreb*

**HARMICINES AS NOVEL ANTIPLASMODIAL LEADS**

### Czech Republic

Dr. Zlatko Janeba

*Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences*

**DEVELOPMENT OF POLYSUBSTITUTED PYRIMIDINES AS POTENT INHIBITORS OF PROSTAGLANDIN E2 PRODUCTION**

Dr. Jan Zitko

*Faculty of Pharmacy in Hradec Králové, Charles University*

**STRUCTURAL MODIFICATIONS OF PYRAZINAMIDE – RATIONAL DESIGN TOWARDS NEW POTENTIAL ANTI-MICROBIAL COMPOUNDS**


### Greece

Dr. Theodora Calogeropoulou

*Institute of Biology, Medicinal Chemistry and Biotechnology*

*National Hellenic Research Foundation*

**CONSTRAINED MILTEFOSINE DERIVATIVES. THE JOURNEY TOWARDS NMT-A2, A NEW DRUG LEAD FOR VISCERAL LEISHMANIASIS**



Assoc. Prof. **Angeliki Kourounakis**

*University of Athens*

**MORPHOLINE: A PRIVILEGED SCAFFOLD FOR THE DEVELOPMENT OF MULTI-TARGET BIOACTIVE MOLECULES**

### **Hungary**

Dr. **Zsuzsa Baranyai**

*MTA-ELTE Research Group of Peptide Chemistry*

**SYNTHESIS AND *IN VITRO* BIOLOGICAL EVALUATION OF DRUG-PEPTIDE CONJUGATES AGAINST GLIOBLASTOMA**

Prof. **Tibor Kurtan**

*University Debrecen*

**BIOACTIVE BENZENE-CONDENSED HETEROCYCLES**

### **Italy**

Prof. **Agostino Marrazzo**

*University of Catania*

**FROM HALOPERIDOL TO NEW SELECTIVE SIGMA RECEPTOR LIGANDS**

### **Poland**

Dr. **Anna Wieckowska**

*Faculty of Pharmacy, Jagiellonian University Medical College*

**SEROTONIN 5-HT<sub>6</sub> RECEPTOR ANTAGONISTS AND CHOLINESTERASE INHIBITORS WITH A $\beta$  ANTIAGGREGATION PROPERTIES IN THE DEVELOPMENT OF MULTIFUNCTIONAL LIGANDS AGAINST ALZHEIMER'S DISEASE**

### **Portugal**

Dr. **Jose Miguel Ferreira de Oliveira**

*LAQV, REQUIMTE, Laboratory of Applied Chemistry, Faculty of Pharmacy, University of Porto*

**REGULATION OF CYCLIN AND CYCLIN-DEPENDENT KINASE EXPRESSION BY 3',4'-DIHYDROXYFLAVONOL IN HUMAN *IN VITRO* MODELS**

### **Slovakia**

Dr. **Lucia Kováčiková**

*Institute of Experimental Pharmacology & Toxicology*

*Slovak Academy of Sciences*

**ISOSTERIC REPLACEMENT BROUGHT MARKEDLY IMPROVED SELECTIVITY OF ALDOSE REDUCTASE INHIBITORS**





**Dr. Magdaléna Májeková**

*Institute of Experimental Pharmacology & Toxicology*

*Slovak Academy of Sciences*

**TARGETING SERCA THROUGH DRUG DESIGN**

**Slovenia**

Assoc. Prof. **Martina Hrast**

*Faculty of Pharmacy, University of Ljubljana*

**COVALENT WARHEADS AS NEW MURA INHIBITORS**

Assoc. Prof. **Izidor Sosič**

*Faculty of Pharmacy, University of Ljubljana*

**DEVELOPMENT OF NON-PEPTIDIC AND SUBUNIT-SELECTIVE INHIBITORS  
OF IMMUNOPROTEASOME**

## INSTRUCTIONS FOR SPEAKERS

Please submit all digital files needed for your presentation in congress room SUN II. Our technician will help you upload all files so everything is ready before the session. To check your presentation please come to the congress room at least 1 hour before the beginning of your session (during the coffee or lunch break). In case your speech has been scheduled for a morning session, please come to check your presentation the day before your presentation.

During your lecture, you will be using the Remote Control to facilitate the progress of your presentation. All speakers are kindly requested to keep to the allocated time for their presentation.

All presentation will be deleted from all the PC used during the congress.

## ABSTRACT BOOK

Abstract book in digital format can be downloaded from:

<https://www.jmmc2019.cz/book-of-abstracts/>





# LIST OF POSTERS

**P-01: IN VITRO AND IN SILICO EVALUATION OF A NEW SERIES OF PYRAZOLINES AS CHOLINESTERASE INHIBITORS**

*M. D. Altintop*

**P-02: DEVELOPMENT OF NOVEL H<sub>2</sub>S-DONOR SIGMA RECEPTOR HYBRIDS FOR THE MANAGEMENT OF PAIN**

*M. Dichiaro, C. Pitino, C. Barbaraci, A. Artacho-Cordón, E. J. Cobos, A. Marrazzo, and E. Amata*

**P-03: 5-ALKYLAMINO-N-PHENYLPYRAZINE-2-CARBOXAMIDES AS POTENTIAL ANTIMYCOBACTERIAL AGENTS**

*W. Ambrożkiewicz and J. Zitko*

**P-04: BJ-1301, A NOX2 AND RECEPTOR TYROSINE KINASE INHIBITOR, SUPPRESSING AUTOCRINE-STIMULATORY FACTORS IN LUNG CANCER**

*B. P. Awasthi, J. Gautam, B.-S. Jeong, and J.-A. Kim*

**P-05: SYNTHESIS OF LUNG TISSUE RETENTIVE PRODRUGS**

*J. Ayre, D. Speed, R. Weaver, G. Vitulli, J. Morrell, C. Bosquillon, J. Redmond, and M. J. Stocks*

**P-06: PROTECTIVE EFFECTS OF 1-BUTYL-3-(5-HYDROXY-3,4,6-TRIMETHYLPYRIDIN-2-YL)THIOUREA AGAINST 4-HNE-INDUCED ADULT RETINAL PIGMENT EPITHELIAL-19 CELL DEATH**

*D. Bae, J. Gautam, J.-A. Kim, and B.-S. Jeong*

**P-07: A SMALL MOLECULE INHIBITOR OF TRANSFORMING ACIDIC COILED-COIL PROTEIN 3 (TACC3): A NOVEL THERAPEUTIC STRATEGY FOR THE TREATMENT OF BREAST CANCER**

*D. Lengerli, O. Akbulut, B. Caliskan, O. Sahin, and E. Banoglu*

**P-08: ABOUT AGGREGATIVE STABILITY OF NANODISPERSIONS BASED ON GADOLINIUM COMPOUNDS FOR OBTAINING DIAGNOSTIC SYSTEMS**

*I. A. Belova, V. S. Makulova, K. I. Kienskaya, and M. V. Sardushkin*

**P-09: MOF COMPOUNDS AS DUAL ACETYL AND BUTYRYLCHOLINESTERASE INHIBITORS**

*A. M. Bondžić, M. V. Senčanski, A. Vujačić Nikezić, M. V. Kirillova, V. André, A. M. Kirillov, and B. P. Bondžić*

**P-10: HYBRID COMPOUNDS COMBINING PYRAZINAMIDE AND P-AMINOSALICYLIC ACID: DESIGN, SYNTHESIS, AND ANTIMICROBIAL EVALUATION**

*G. Bouz, M. Doležal, and J. Zitko*

**P-11: DISCOVERY OF 3-[3-(PYRROLIDIN-1-YL)PROPYL]-1,2-BENZOXAZOLE DERIVATIVES TARGETING BEHAVIOURAL AND PSYCHOLOGICAL SYMPTOMS OF DEMENTIA (BPSD)**

*A. Bucki, M. Marcinkowska, J. Śniecikowska, A. Zagórska, M. Pawłowski, M. Głuch-Lutwin, A. Siwek, A. Partyka, M. Jastrzębska-Więsek, A. Wesółowska, P. Mierzejewski, and M. Kotackowski*

**P-12: DESIGN, SYNTHESIS AND MOLECULAR MODELING OF POTENTIAL LIGANDS OF IONOTROPIC GLUTAMATE RECEPTORS**

*P. Chałupnik and E. Szymańska*

**P-13: FLUORINE-18 ISOTOPE LABELING FOR POSITRON EMISSION TOMOGRAPHY IMAGING. DIRECT EVIDENCE FOR DBPR211 AS A PERIPHERALLY RESTRICTED CB1 INVERSE AGONIST**

*C. P. Chang, H. L. Huang, J. K. Huang, M.S. Hung, C. H. Wu, J. S. Song, C. J. Lee, C. S. Yu, and K. S. Shia*

**P-14: DISCOVERY OF 6-HETEROARYLAMINO-2,4,5-TRIMETHYLPYRIDIN-3-OLS FOR ANTI-INFLAMMATORY BOWEL DISEASE**

*C. L. Chaudhary, S. W. Park, S. Banskota, T.-G. Nam, J.-A. Kim, and B.-S. Jeong*

**P-15: NEW CLASS OF TRPA1 ANTAGONISTS AND/OR PDE INHIBITORS BASED ON PURINE-2,6-DIONE SCAFFOLD AS POTENTIAL ANALGESIC AGENTS**

*G. Chłoń-Rzepa, M. Ślusarczyk, A. Jankowska, A. Bucki, A. Gawalska, M. Pawłowski, A. Świerczek, K. Pocięcha, E. Wyska, M. Zygmont, and G. Kazek*

**P-16: UB-EV-52, A NEW CHEMICAL PROBE TO ESTABLISH SOLUBLE EPOXIDE HYDROLASE AS A TARGET FOR THE TREATMENT OF ALZHEIMER'S DISEASE**

*S. Codony, C. Griñan-Ferré, E. Pujol, J. Yang, R. Leiva, C. Escolano, D. Puigoriol-Illamola, J. Companys-Aleman, R. Corpas, C. Sanfeliu, C. Morisseau, B. D. Hammock, C. Galdeano, M. Pallàs, and S. Vázquez*

**P-17: CARBOHYDRATE-BASED POTENTIAL ANTIMICROBIAL DRUGS AND GLYCOPEPTIDES WITH OLD AND NEW THERAPEUTIC GOALS**

*M. Csávás, L. Malinová, G. Jančaříková, S. Le Thai, Zs. Szűcs, P. Herczegh, M. Wimmerová, and A. Borbás*

**P-18: SYNTHESIS OF BIOCONJUGATES OF FERROCENE AND PYRIMIDINE NUCLEOBASES AND CHEMOSENSITIVITY OF HUMAN LUNG EPITHELIAL CELLS**

*S. Djaković, J. Lapić, M. Toma, D. Šakić, V. Vrček, A. M. Marjanović Čermak, K. Ilić, and I. Pavičić*

**P-19: ASSOCIATED USE OF HETEROCYCLIC COMPOUNDS WITH CHEMOTHERAPY TO REDUCE SIDE EFFECTS AND INCREASE ANTITUMOR ACTIVITY IN THE EXPERIMENT**

*M. Dosina, A. Kvachenok, S. Pashkevich, A. Kletskov, V. Potkin, R. Aleksandrova, and V. Kulchitsky*

**P-20: A NOVEL 3-METHYLIDENEQUINOL-4-ONE DERIVATIVE INDUCES APOPTOSIS AND DOWNREGULATES MAPK PATHWAY IN LEUKEMIA CELL LINE**

*J. Drogosz, K. Gach-Janczak, A. Długosz-Pokorska, J. Koszuk, and A. Janecka*

**P-21: RATIONAL DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL HDHODH INHIBITORS**

*N. C. Fohrmann, K. Pfaff, M. Winkler, G. Querat, J. Kirchmair, and C. Meier*

**P-22: PROMISING INHIBITORY ACTIVITY OF FLAVONOIDS AGAINST IMPORTANT TARGETS RELATED WITH TYPE 2 DIABETES MELLITUS**

*C. Proença, M. Freitas, D. Ribeiro, Sara M. Tomé, Alberto N. Araújo, A. M. S. Silva, P. A. Fernandes, and E. Fernandes*

**P-23: ANTICANCER ACTIVITY OF A NEW  $\alpha$ -METHYLENE- $\delta$ -LACTONE DL-247 IN SELECTED CANCER CELL LINES**

*K. Gach-Janczak, A. Długosz-Pokorska, J. Drogosz, R. Jakubowski, J. Szymański, T. Janecki, and A. Janecka*

**P-24: METAL-CHELATING AGENTS WITH IMPROVED INHIBITORY ACTIVITY AGAINST HEPATITIS C VIRUS**

*E. Giannakopoulou, V. Pardali, E. Frakolaki, V. Myrianthopoulos, E. Mikros, R. Bartenschlager, N. Vassilaki, and G. Zoidis*

**P-25: THYMOL 1,3,5-TRIAZINE DERIVATIVES AS NEW POTENT LIGANDS FOR 5-HT<sub>6</sub> SEROTONIN RECEPTOR**

*J. Handzlik, M. Więcek, M. Piłuka, D. Furgał, R. Kurczab, G. Satała, D. Łażewska, and K. Kieć-Kononowicz*

**P-26: IN VITRO PROFILING OF NEW ANTIMYCOBACTERIAL COMPOUNDS AND THEIR PEPTIDE CONJUGATES**

*L. Horváth, M. Krátký, Zs. Baranyai, V. Pflégr, J. Vinšová, and Sz. Bősze*

**P-27: SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL N-SUBSTITUTED BENZIMIDAZOLE ACRYLONITRILES**

*M. Hranjec, N. Perin, A. Beč, L. Persoons, and D. Daelemans*

**P-28: SYNTHESIS OF INDAZOLE-BASED INHIBITORS AS POTENTIAL AGENTS AGAINST ABNORMAL TAU FORMATION**

*J.-H. Hsu, Y.-F. Liao, and M.-K. Hu*

**P-29: EXPLORATION OF KINASE INHIBITORS AS AUTOPHAGIC MODULATORS OF A $\beta$  PRODUCTION**

*M.-K. Hu, Y.-F. Liao, A.-S. Liou, J.-H. Hsu, and F.-C. Yang*

**P-30: NEW TRPV1 CHANNEL ANTAGONISTS WITH ANTICONVULSANT AND ANTINOCICEPTIVE ACTIVITY**

*M. Jakubiec, M. Zagaja, M. Andres-Mach, A. Szewczyk, M. Abram, S. Mogiński, G. Latacz, B. Szulczyk, and K. Kamiński*

**P-31: DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL AMINOALKYLAMIDE DERIVATIVES AS 5-HT<sub>1A</sub>/5-HT<sub>7</sub> RECEPTORS LIGANDS AND PHOSPHODIESTERASES 4/7 INHIBITORS**

*A. Jankowska, G. Satała, M. Kołaczkowski, M. Głuch-Lutwin, A. Bucki, A. Świerczek, K. Pociecha, B. Mordyl, A. Lubelska, G. Latacz, A. Gawalska, M. Jamrozik, A. Partyka, A. Wesołowska, A. J. Bojarski, E. Wyska, J. Handzlik, M. Pawłowski, and G. Chłoń-Rzepa*

**P-32: NOVEL LIPOPHILIC CAGED ADENOSINE NUCLEOTIDES**

*N. Jeschik and C. Meier*

**P-33: SYNTHESIS OF PHOSPHORYLATED 13 $\alpha$ -ESTRONE DERIVATIVES AS POTENTIAL OATP2B1 INHIBITORS**

*R. Jójárt, P. Trunzel-Nagy, M. Klement, J. Wöfling, R. Rigó, O. Ungvári, Cs. Özvegy-Laczkó, and E. Mernyák*

**P-34: DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF PYRAZINE DERIVATIVES**

*M. Juhász, J. Zítka, and M. Doležal*

**P-35: MULTI-TARGET LIGANDS OF AMINERGIC GPCRS FOR POTENTIAL TREATMENT OF MENTAL DISEASES**

*Ag. A. Kaczor, M. Kondej, P. Stępnicki, O. Koszła, J. Żuk, A. Bartyzel, K. M. Targowska-Duda, T. M. Wróbel, D. Bartuzi, E. Kędzierska, G. Biała, D. Matosiuk, A. G. Silva, and M. Castro*

**P-36: AMINE DERIVATIVES OF 5-ARYLIDENEIMIDAZOLONES AS POTENTIAL ANTIBIOTIC ADJUVANTS**

*An. Kaczor, K. Witek, S. Alibert, J. M. Pages, E. Karczewska, K. Kieć-Kononowicz, and J. Handzlik*

**P-37: NEW 2-ARYLQUINONES AND THEIR ANTIPLASMODIAL AND TRYPANOCIDAL PROPERTIES**

*M.-M. Kalt and A. Presser*

**P-38: STRUCTURE – IN VITRO CARDIOPROTECTIVE ACTIVITY RELATIONSHIPS STUDY OF NOVEL DEXRAZOXANE DERIVATIVES**

*G. Karabanovich, A. Jirkovská, H. Jansová, T. Šimůnek, and J. Roh*

**P-39: DESIGN, SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF NOVEL DERIVATIVES AS TYROSYL-DNA PHOSPHODIESTERASE 1 AND/OR 2 INHIBITORS**

*M. Karelou, K. Agama, Y. Pommier, and I. K. Kostakis*

**P-40: ANTI-CANCER ACTIVITY OF 6-(4-(HYDROXYDIPHENYLMETHYL)PIPERIDIN-1-YL)-2,4,5-TRIMETHYLPYRIDIN-3-OL**

*U. Karmacharya, J. Gautam, B.-S. Jeong, and J.-A. Kim*

**P-41: MONOAMINE OXIDASE B INHIBITORY ACTIVITY OF 4-IMIDAZOLONE DERIVATIVES**

*K. Kieć-Kononowicz, A. Olejarz-Maciej, A. Doroz-Płonka, A. Chudzik, T. Rządca, and D. Łażewska*

**P-42: CAVER WEB: ANALYSIS OF PROTEIN TUNNELS AND LIGAND BINDING TRAJECTORIES IN DRUG DESIGN**

*P. Kokkonen, J. Stourac, J. Filipovic, O. Vavra, G. Pinto, D. Bednar, and J. Damborsky*

**P-43: D2AAK1 AS A MULTI-TARGET LIGAND OF AMINERGIC GPCRS – OPTIMIZATION OF SYNTHESIS**

*M. Kondej, P. Stępnicki, T. M. Wróbel, D. Matosiuk, and A. A. Kaczor*

**P-44: NEW AGENTS SUPPRESSING MYCOBACTERIUM ABSCESSUS: SMALL MOLECULES AND THEIR PEPTIDE CONJUGATES**

*M. Krátký, L. Horváth, Zs. Baranyai, R. Vosátka, Sz. Bősze, and J. Vinšová*

**P-45: (4-OXO-2-THIOXOTHIAZOLIDIN-3-YL)ACETIC ACID DERIVATIVES AS EFFECTIVE ALDOSE REDUCTASE INHIBITORS**

*M. Kučerová-Chlupáčová, M. Šoltéssová Prnová, J. Tremel, J. Balleková, S. Michalíková, D. Haláková, M. Májeková, and M. Štefek*

**P-46: THE INFLUENCE OF AN AMINE MOIETY FOR HISTAMINE H<sub>3</sub> RECEPTOR AFFINITY AND MONOAMINE OXIDASE B INHIBITORY ACTIVITY**

*D. Łażewska, A. Siwek, A. Olejarz-Maciej, A. Doroz-Płonka, and K. Kieć-Kononowicz*

**P-47: DESIGN OF NEW BIOLOGICAL ACTIVE COMPOUNDS STARTING FROM NATURAL COUMARINS**

*A. V. Lipeeva, E. E. Schults, D. O. Zakharov, T. S. Frolova, M. P. Dolgikh, and T. G. Tolstikova*

**P-48: THE SYNTHESIS AND CELLULAR EFFECTS OF NOVEL 1,3,5-TRIAZINE DERIVATIVES IN DLD AND HT-29 HUMAN COLON CANCER CELL LINES**

*D. Maliszewski, A. Wróbel, B. Kolesińska, Z. Kamiński, A. Tankiewicz-Kwedlo, and D. Drozdowska*

**P-49: NMR STRUCTURAL STUDIES AND ANTICANCER ACTIVITY OF NOVEL  $\beta$ -PEPTIDES**

*A. B. Mantsyov, M. N. Sokolov, P. M. Ivantcova, V. I. Polshakov, and K. V. Kudryavtsev*

**P-50: DEPENDENCE OF ANTIMICROBIAL PROPERTIES OF ZINC OXIDE NANOPARTICLES OF THE FORM AND SIZE**

*G. T. Mazitova, I. A. Butorova, O. A. Nechaeva, D. A. Ivanova, and K. I. Kienskaya*

**P-51: SYNTHESIS OF NOVEL HETEROCYCLIC COMPOUNDS WITH POTENTIAL ANTIMYCOBACTERIAL ACTIVITY**

*I. Melnikova, G. Karabanovich, L. Bartoš, J. Stolaříková, V. Klimešová, A. Hrabálek, and J. Roh*

**P-52: CONFRONTING CHOLINERGIC AND GLUTAMATERGIC MECHANISMS OF ALZHEIMER'S DISEASE WITH A NOVEL CLASS OF MULTITARGET AGENTS**

*F. Javier Pérez-Areales, A. L. Turcu, M. Barniol-Xicota, C. Pont, D. Pivetta, A. Espargaró, M. Bartolini, A. De Simone, V. Andrisano, B. Pérez, D. Vilchez, F. J. Luque, R. Sabate, F. X. Sureda, S. Vázquez, and D. Muñoz-Torrero*

**P-53: NEW DICARBOXIMIDES TARGETING ABCF1 PROTEIN SHOW POTENT ANTICANCER AND IMMUNOMODULATORY ACTIVITIES**

*K. Królewska-Golińska, J. Kaźmierczak-Barańska, M. Cieślak, I. Stukan, U. Wojda, M. Napiórkowska, and B. Nawrot*

**P-54: DESIGN, SYNTHESIS AND EVALUATION OF N-(PYRIDIN-2-YL)BENZAMIDES AND N-(PYRIDIN-2-YL)-2-PHENYLACETAMIDES AS POTENTIAL ANTIMYCOBACTERIAL AGENTS**

*D. Nawrot, M. Doleżał, and J. Žitko*

**P-55: NEW HYBRID COMPOUNDS, DERIVATIVES OF 3-(3-METHYLTHIOPHEN-2-YL) AND (BENZO[B]THIOPHEN-2-YL)-PYRROLIDINE-2,5-DIONE WITH POTENTIAL ANTICONVULSANT ACTIVITY**

*J. Obniska, M. Góra, A. Czopek, and A. Rapacz*

**P-56: SYNTHESIS AND BIOLOGICAL ACTIVITY OF QUATERNARY SALTS OF 3-N-DODECYLAMINOQUINUCLIDINE**

*R. Odžak, M. Šprung, B. Soldo, A. Maravić, L. Bazina, A. Radman Kastelic, T. Hrenar, and I. Primožič*

**P-57: IMPACT OF THE SUPRAMOLECULAR ORGANISATION OF PYRENE – QUINOLINE CONJUGATES ON THEIR INTERACTION WITH DS – DNA**

*I. Orehovec, D. Glavač, I. Dokli, M. Gredičak, and I. Piantanida*

**P-58: IN VITRO EVALUATION OF A NEW SERIES OF BIS-PYRAZOLINES AS ANTIFUNGAL AGENTS**

*A. Özdemir, B. Sever, and M. D. Altıntop*

**P-59: IDENTIFICATION OF THIOSEMICARBAZIDES FOR INHIBITION OF TOXOPLASMA GONDII GROWTH IN VITRO**

*A. Paneth, L. Węglińska, A. Bekier, E. Stefaniszyn, M. Wujec, N. Trotsko, and K. Dzitko*

**P-60: STRUCTURE-BASED DESIGN AND SYNTHESIS OF PUTATIVE BRAF<sup>V600E</sup> INHIBITORS AS ANTICANCER AGENTS**

*G. E. Magoulas, E. Kritsi, M. Koufaki, D. Papahatjis, M. Zervou, and T. Calogeropoulou*

**P-61: N-ACETOHYDROXAMIC ACID DERIVATIVES AS METAL-CHELATING AGENTS AGAINST PARASITIC DISEASES**

*V. Pardali, E. Giannakopoulou, M. C. Taylor, J. M. Kelly, and G. Zoidis*

**P-62: NOVEL 1-AMINO-4-PHENYLBUTAN-2-OL DERIVATIVES AS MULTIFUNCTIONAL LIGANDS INHIBITING BUTYRYLCHOLINESTERASE AND  $\beta$ -SECRETASE**

*A. Pasięka, D. Panek, N. Szałaj, J. Godyrń, J. Jończyk, J. Tabor, D. Knez, A. Więckowska, M. Bajda, S. Gobec, and B. Malawska*

**P-63: “LEGO” AND GREEN SYNTHETIC STRATEGY IN EARLY DRUG-DRUG CONJUGATES (DDCs) DESIGN**

*A. Pawełczyk, K. Sowa-Kasprzak, D. Olender, and L. Zaprutko*

**P-64: SYNTHESIS AND PHARMACOLOGICAL EVALUATION OF N-{4-[2-(4-ARYLPIPERAZIN-1-YL) ETHYL] PHENYL}ARYLAMIDES**

*J. Penjišević, D. Andrić, S. Dukić-Stefanović, T. Spalholz, P. Brust, and S. Kostić-Rajačić*

**P-65: 2<sup>ND</sup> GENERATION OF HARMICINES AS POTENTIAL ANTIPLASMODIAL AGENTS**

*I. Perković, G. Poje, and Z. Rajić*

**P-66: SYNTHESIS AND EVALUATION OF NOVEL ISONIAZID-BASED COMPOUNDS AS POTENTIAL ANTIMYCOBACTERIAL AGENTS**

*V. Pflégr, M. Krátký, S. Bruno, J. Stolaříková, L. Horváth, Sz. Bősze, and J. Vinšová*

**P-67: PREPARING AND ANTIPROTEASOMAL ACTIVITY OF SALICYLAMIDES-BASED PSEUDOPEPTIDES WITH ACRYLAMIDE MOIETY**

*E. Pilařová, A. Imramovský, K. Pauk, Pratibha Magar, R. Jorda, and V. Kryštof*

**P-69: A SMALL-MOLECULE INHIBITOR OF HEME OXYGENASE-1 ENHANCES METFORMIN ANTIPROLIFERATIVE ACTIVITY**

*V. Pittalà, M. Raffaele, L. Salerno, A. N. Fallica, V. Ciaffaglione, V. Sorrenti, and L. Vanella*

**P-70: ANTICANCER SCREENING OF SERIES OF SUBSTITUTED THIOSEMICARBAZIDE WITH PHENOXYACETIC GROUP**

*M. Pitucha, A. Korga, P. Kozyra, M. Iwan, and A. Pachuta-Stec*

**P-71: DIPEPTIDYL PEPTIDASE-4 INHIBITION BY FLAVONOIDS IS HINDERED IN PROTEIN RICH ENVIRONMENTS**

*C. Proença, M. Freitas, D. Ribeiro, S. M. Tomé, A. N. Araújo, A. M. S. Silva, P. A. Fernandes, and E. Fernandes*

**P-72: NEW DIARYLUREAS AS HRI ACTIVATORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND RELATED METABOLIC DISORDERS**

*E. Pujol, M. Zarei, J. Pizarro, M. I. Loza, J. M. Brea, M. Vázquez-Carrera, and S. Vázquez*

**P-73: SYNTHESIS, ANTI-PROLIFERATIVE ACTIVITY AND 3D-QSAR ANALYSIS OF NOVEL SERIES OF AMIDINO-SUBSTITUTED ARYL-BISBENZAZOLES**

*L. Racané, L. Ptiček, P. Grbčić, S. Kraljević Pavelić, and B. Bertoša*

**P-74: QUINOLINE FUMARDIAMIDES AS NOVEL QUORUM SENSING INHIBITORS**

*Z. Rajić, J. Z. Patel, K. Savijoki, A. Fallarero, J. Yli-Kauhaluoma, M. Beus, and B. Zorc*

**P-75: SYNTHESIS AND EVALUATION OF NEW PHENOLIC CINNAMIC ACID DERIVATIVES AS POTENTIAL SELECTIVE COX-2 INHIBITORS**

*D. Ribeiro, C. Proença, C. Varela, J. Janela, E. Tavares da Silva, E. Fernandes, and F. Roleira*

**P-76: RIBAVIRIN-INTERFERON INTERMOLECULAR COMPLEXES IN AQUA SOLUTIONS**

*M. V. Sardushkin, O. V. Zavyalova, A. M. Kusmaev, R. R. Ibragimova, and K. I. Kienskaya*

**P-77: DISCOVERY OF NOVEL HUMAN DNA TOPOISOMERASE II INHIBITORS THROUGH SCREENING OF BACTERIAL TOPOISOMERASE INHIBITORS' LIBRARY**

*Ž. Skok, M. Durcic, N. Zidar, L. Peterlin Mašič, D. Kikelj, and J. Ilaš*

**P-78: SELECTIVE pERK1/2- OR  $\beta$ -ARRESTIN- PREFERRING 5-HT<sub>1A</sub> RECEPTOR BIASED AGONISTS WITH DIVERSIFIED THERAPEUTIC-LIKE VS. SIDE EFFECTS PROFILE**

*J. Sniecikowska, M. Gluch-Lutwin, A. Bucki, A. Wieckowska, A. Siwek, M. Jastrzebska-Wiesek, A. Partyka, D. Wilczynska, A. Wesolowska, M. Pawlowski, M. Varney, A. Newman-Tancredi, and M. Kolaczkowski*

**P-79: SYNTHESIS OF SELECTED ANALOGUES OF CURCUMIN**

*K. Sowa-Kasprzak, D. Olender, A. Pawełczyk, and L. Zaprutko*


**P-80: ON RESIN CLICK CHEMISTRY Cu (I) MEDIATED SYNTHESIS OF NOVEL OPIOID AGONISTS**

*A. Stefanucci, S. Pieretti, M. P. Dimmito, A. Della Valle, and A. Mollica*

**P-81: SYNTHESIS, CHIRAL SEPARATION AND BIOLOGICAL ACTIVITY OF ( $\pm$ )-*trans*- $\beta$ -LACTAM UREAS**

*M. Jurin, V. Stepanić, and M. Roje*





**P-82: DESIGN AND SYNTHESIS OF MYOSTATIN INHIBITORY CYCLIC 22-MER PEPTIDES**

*C. Rentier, K. Takayama, M. Saitoh, A. Nakamura, H. Ikeyama, A. Taguchi, A. Taniguchi, and Y. Hayashi*

**P-83: SELECTIVE PHOTOOXYGENATION OF MYOSTATIN USING PEPTIDE-CATALYST CONJUGATE**

*A. Taniguchi, H. Okamoto, S. Usami, A. Taguchi, K. Takayama, and Y. Hayashi*

**P-84: SYNTHESIS AND TUBERCULOSTATIC ACTIVITY OF SUBSTITUTED DIHYDROAZOLOPYRIMIDINES**

*Yu. A. Titova, E. S. Filatova, O. V. Fedorova, G. L. Rusinov, and V. N. Charushin*

**P-85: FORMULATION 2 IN 1 SULFATE-FREE BASED SHAMPOO WITH AN ANTIMICROBIAL ACTIVITY**

*E. V. Tolmacheva, K. I. Kienskaya, N. I. Makhova, and I. A. Butorova*

**P-86: DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF IMIDAZOLE-BASED COMPOUNDS AS ANTIPARASITE AGENTS**

*V. Tudino, F. Saccoliti, V. N. Madia, A. De Leo, R. Brun, L. M. Podust, A. Messori, L. Scipione, R. Costi, and R. Di Santo*

**P-87: NOVEL NMDA-RECEPTOR BLOCKERS AGAINST ALZHEIMER'S DISEASE**

*A. L. Turcu, D. Martínez-Falguera, E. Gratacòs-Batalle, D. Soto, F. X. Sureda, and S. Vázquez*

**P-88: STRUCTURAL EXPLORATION OF CINNAMATE-BASED PHOSPHONIC ACIDS AS INHIBITORS OF BACTERIAL UREASE**

*V. Ntatsopoulos, K. Macegoniuk, A. Mucha, Ł. Berlicki, and S. Vassiliou*

**P-89: SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL LIPOYL/POLYPHENOLIC HYBRIDS**

*A. Pagoni, A. diStefano, and S. Vassiliou*

**P-90: A NEW FAMILY OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS: *IN VITRO* PROFILING AND *IN VIVO* EVALUATION IN A MURINE MODEL OF ACUTE PANCREATITIS**

*S. Vázquez, S. Codony, J. Pizarro, M. I. Loza, J. M. Brea, C. Morisseau, B. D. Hammock, and M. Vázquez-Carrera*

**P-91: SYNTHESIS AND BIOLOGICAL ACTIVITY OF NOVEL TRIMETHOPRIM ANALOGUES AS POTENTIAL MINOR GROOVE BINDERS AGENTS OF DNA, AS WELL AS INHIBITORS OF DHFR ENZYME AND HUMAN TOPOISOMERASE II**

*A. Wróbel, D. Maliszewski, and D. Drozdowska*

**P-92: NITROIMIDAZOLE-THIOSEMICARBAZIDES AS ANTIPARASITIC AGENTS**

*M. Wujec, P. Kołodziej, A. Paneth, A. Bogucka-Kocka, K. Dziduch, Ł. Popiołek, and K. Paruch*

**P-93: TOWARDS THE DEVELOPMENT OF NOVEL ANTI-HBV AGENTS: DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF *N*-HYDROXYIMIDES AS RNASEH INHIBITORS**

*V. Pardali, E. Giannakopoulou, T. Edwards, J. Tavis, and G. Zoidis*

**P-94: MOLECULAR MODELLING STUDY OF ALLOSTERIC MODULATION OF DOPAMINE D<sub>2</sub> RECEPTOR**

*J. Žuk, D. Bartuzi, and A. A. Kaczor*

# Advion

Mass Spectrometry for Chemists

Reaction Monitoring &  
Compound Identification  
in 30 seconds



Direct mass analysis  
of solid and liquid  
samples - ASAP®



Direct mass analysis  
from TLC-plates -  
Plate Express™



For more Information:  
[central-europe@advion.com](mailto:central-europe@advion.com)  
[www.expressioncms.com](http://www.expressioncms.com)

# JOURNALS FROM BENTHAM SCIENCE



**EDITOR-IN-CHIEF**  
Atta-ur-Rahman, FR5  
UK

## Current Medicinal Chemistry

Volumes 26, 42 Issues, 2019  
ISSN: 1875-533X (Online)  
ISSN: 0929-8673 (Print)

### AIMS & SCOPE

Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth/mini reviews and guest edited thematic issues written by leaders in the field covering a range of the current topics in medicinal chemistry. The journal also publishes reviews on recent patents. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

### Abstracted and Indexed in:

- Science Citation Index®
- Journal Citation Reports/Science Edition
- InCites
- Science Citation Index Expanded
- Index to Scientific Reviews®
- Biochemistry and Biophysics Citation Index®
- Current Contents® - Life Sciences
- Research Alert
- BIOSIS
- BIOSIS Previews
- BIOSIS Reviews Reports and Meetings
- Prous Science Integrity®
- Many More...



**EDITOR-IN-CHIEF**  
Dimitra Hadjipavlou-Litina  
Greece

## Medicinal Chemistry

Volume 15, 8 Issues, 2019  
ISSN: 1875-6638 (Online)  
ISSN: 1573-4064 (Print)

### AIMS & SCOPE

Medicinal Chemistry a peer-reviewed journal, aims to cover all the latest outstanding developments in medicinal chemistry and rational drug design. The journal publishes original research, full-length/mini-review articles and guest edited thematic issues covering recent research and developments in the field. Articles are published rapidly by taking full advantage of Internet technology for both the submission and peer review of manuscripts. Medicinal Chemistry is an essential journal for all involved in drug design and discovery.

### Abstracted and Indexed in:

- Science Citation Index Expanded (SciSearch®)
- Journal Citation Reports/Science Edition
- InCites
- BIOSIS Previews
- BIOSIS Reviews Reports and Meetings
- MEDLINE/PubMed/Index Medicus
- Scopus
- EMBASE
- Chemical Abstracts Service/SciFinder
- ProQuest
- ChemWeb
- Google Scholar
- Genamics JournalSeek
- Many More...



**EDITOR-IN-CHIEF**  
Allen B. Reitz  
USA

## Current Topics in Medicinal Chemistry

Volume 19, 32 Issues, 2019  
ISSN: 1873-4294 (Online)  
ISSN: 1568-0266 (Print)

### AIMS & SCOPE

Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.

### Abstracted and Indexed in:

- Science Citation Index Expanded™
- Journal Citation Reports/Science Edition
- InCites
- Index to Scientific Reviews®
- Biochemistry & Biophysics Citation Index™
- Current Contents®
- BIOSIS
- BIOSIS Previews
- BIOSIS Reviews Reports and Meetings
- ISI Alerting Services
- MEDLINE/PubMed/Index Medicus
- Scopus
- EMBASE/Excerpta Medica
- Chemical Abstracts Service/SciFinder
- ProQuest
- ChemWeb



**BENTHAM  
SCIENCE**

- ➔ Publishing Peer Reviewed Articles Rapidly
- ➔ Print & Online
- ➔ Free Online Trials for Institutions

**20%**  
Subscription  
Discount

To Attendees of the Conference  
To Avail, Quote "BSPCNF2019"  
at [www.eurekaselect.com](http://www.eurekaselect.com)  
or email at [marketing@benthamscience.net](mailto:marketing@benthamscience.net)

## SOCIAL EVENTS

### Welcome Cocktail – DiJazzTiva concert

**Date:** June 27, 2019

**Time:** 18:00–19:30

**Venue:** Pyramida hotel

**Price:** included in the registration fee

**Price for accompanying person:** 25 EUR

### Congress Dinner

**Date:** June 28, 2019

**Time:** 19:30–22:30

**Venue & Address:** The Great Monastery Restaurant (Velká klášterní restaurace), Strahovské nádvoří 302, Prague 1



**Meeting point:** 19:20 at reception of Pyramida hotel, distance approximately 10 minutes by walk

**Price:** 45 EUR per person

The Congress Dinner will be held at the Great Monastery Restaurant, located in the premises of the Premonstratensian Strahov Monastery, just a few steps from the Prague Castle.

Premonstratensian monastery at Strahov was founded in 1140 by the Bishop of Olomouc, Jindřich Zdík, with the support of the Czech Prince, and later king Vladislav II. A huge complex standing at the outset of the Royal Way offers pleasant dining in the historical Great Monastery Restaurant.

For centuries, Strahov Monastery has been a centre of culture and art. Since the 18<sup>th</sup> century, a valuable painting collection has been situated in its picture gallery. Strahov's library is also very interesting and precious.

# TOURS

## Premiant Tours

Jindřišská 941/24, 110 00 Praha 1, Czech Republic

**Phone:** +420 606 600 123

**E-mail:** [congress@premiant.cz](mailto:congress@premiant.cz)

The tours can be booked via email or phone till June 28, 2019.

### T3 – Grand City Tour + Prague Castle + Charles Bridge



**Date:** June 27 or June 30, 2019

**Departures:** 11:15 am

**Duration:** 3,5 hours

**Price:** Adults 27,20 EUR; students 24 EUR

### T9 – Český Krumlov – UNESCO



**Date:** June 27 or June 30, 2019

**Departures:** 8:45 am

**Duration:** approx. 11 hours

**Price:** Adults 83,60 EUR; students 83,60 EUR

### T10 – Karlovy Vary and Moser Factory



**Date:** June 27 or June 30, 2019

**Departures:** 8:45 am

**Duration:** approx. 9,5 hours

**Price:** Adults 67,60 EUR; students 63,60 EUR



## PARTNERS

The organizers would like to express their thanks to the following partners for their support:

### Bronze Partner

**European headquarters:** Advion Ltd.,  
Harlow Enterprise Hub, Kao Hockham Building,  
Edinburgh Way, Harlow, CM20 2NQ, United Kingdom  
<https://advion.com/>, [info@advion.com](mailto:info@advion.com)

### Partners



### Media Partner




### European Federation for Medicinal Chemistry – Sponsored event



**EFMC**  
European Federation  
for Medicinal Chemistry

# FLOOR PLAN



## Exhibition hours

June 27, 2019	June 28, 2019	June 29, 2019	June 30, 2019
Thursday	Friday	Saturday	Sunday
13:00–19:30	08:30–19:00	08:00–18:30	08:30–14:00

## Exhibition dismantle

June 27, 2019 from 14:00



# GENERAL INFORMATION

## Congress Venue

### Orea Hotel Pyramida

Bělohorská 24, 169 00 Prague 6, Czech Republic

<https://www.hotelpyramida.cz/en/conferences-and-events/>



## Registration

### On-Site Registration Fees

Academia fee	560 EUR
Industry – delegates of Companies without exhibition space	715 EUR
Student Fee	210 EUR

*Registration fees include 21% VAT.*

### The Registration Fee Includes:

- Admission to all scientific sessions
- Admission to the Exhibition area
- Congress materials
- Coffee breaks
- Welcome cocktail

### Opening Hours

June 27, 2019	June 28, 2019	June 29, 2019	June 30, 2019
Thursday	Friday	Saturday	Sunday
13:00–19:00	08:00–19:00	08:00–18:30	08:30–14:30



## Badges

Participants will receive a name badge upon registration. Everyone is kindly requested to wear the name badge when attending the Congress. Only participants who are wearing their name badge will be admitted to the lecture halls.

Name badges are color-coded as follows:

DELEGATES	
ORGANISING COMMITTEE	
ORGANISER	

## Wi-Fi Connection

Free Wi-Fi connection is at disposal in all the Congress meeting rooms and foyer area.

**Network: Pyramida**

**No password is required.**

## Certificate of Attendance

Certificate of attendance will be sent via e-mail in pdf form upon request.





## GOOD TO KNOW

### Climate

The climate is a mixture of ocean and continental influences. The month of June is characterized by gradually rising daily temperatures, with daily highs increasing from 20 °C to 22 °C over the course of the month, exceeding 28 °C. The average probability that some form of precipitation will be observed in a given day is 60 %, with little variation over the course of the month. Throughout June, the most common forms of precipitation are moderate rain, thunderstorms, and light rain.

You can find the current weather at [www.weather.com](http://www.weather.com).

### Currency and Banking

Czech Crowns are the official currency in the Czech Republic. Foreign currency exchange is available at Václav Havel Airport Prague and at most hotels, banks and exchange offices throughout the city. International credit cards are accepted for payment in hotels, restaurants and shops. Paying by cash in Euro is also possible in some restaurants and shops.

For the official exchange rates on the website of the [www.cnb.cz](http://www.cnb.cz).

### Important Telephone Numbers

**112: General Emergency for Europe**

**150: Fire**

**155: Ambulance**

**156: Prague Police**

**158: Police**

### Liability and Insurance

The organisers do not accept responsibility for individual medical, travel or personal insurance.

All participants are strongly advised to take out their own personal insurance before travelling to the Congress.

### Programme Changes

The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

### Official Language

The official language of the Conference is English.



# Notes

A series of horizontal dotted lines extending across the page, providing a space for handwritten notes.



A series of horizontal dotted lines spanning the width of the page, providing a template for writing.



A series of horizontal dotted lines spanning the width of the page, providing a template for writing or drawing.



A series of horizontal dotted lines spanning the width of the page, providing a template for writing.



A series of horizontal dotted lines spanning the width of the page, providing a template for writing.

2019  
**JMMC**

Prague

JOINT MEETING ON MEDICINAL CHEMISTRY

Prague, June 27–30, 2019

[www.jmmc2019.cz](http://www.jmmc2019.cz)